Achievements
- Cover Story: On a Mission to Advance Global Healthcare
Zenovel was featured as the Cover Story in Business Connect Magazine, recognizing our journey as a global pharmaceutical services partner delivering excellence in quality, compliance, and innovation across the product lifecycle. The feature highlights our growth story, leadership vision, global expansion, AI-driven regulatory solutions, commitment to quality beyond compliance, and our mission to help pharmaceutical organizations accelerate innovation while ensuring regulatory excellence.
The feature also showcases Zenovel’s commitment to delivering end-to-end pharmaceutical solutions through scientific expertise, operational excellence, and a client-centric approach. From GCP and GMP compliance to Regulatory Affairs and strategic consulting, we help organizations confidently navigate complex regulatory landscapes while accelerating product development and maintaining the highest quality standards.
As we continue to grow, we remain committed to setting new benchmarks in quality, compliance, and innovation while empowering pharmaceutical organizations worldwide with trusted expertise and regulatory excellence.
- Top 10 Pharmaceutical Regulatory Consultants – 2024
Zenovel was proudly featured by India Pharma Outlook among the Top 10 Pharmaceutical Regulatory Consultants – 2024. The publication highlights our expertise in GCP, GMP, and Regulatory Affairs, along with our commitment to helping pharmaceutical organizations achieve regulatory excellence through quality-driven and innovative solutions.
This recognition reflects our ability to navigate complex regulatory requirements, support global compliance, and deliver trusted consulting services that drive operational excellence across the pharmaceutical industry.
The achievement reinforces Zenovel’s commitment to quality, innovation, and client success as a trusted global pharmaceutical consulting partner.
- Top 10 Most Promising Contract Research Organizations – 2022
Zenovel was recognized by SiliconIndia Magazine as one of the Top 10 Most Promising Contract Research Organizations (CROs) – 2022, acknowledging our commitment to delivering high-quality clinical research, regulatory affairs, and GMP consulting services. The feature highlights our client-centric approach, experienced global team, robust quality systems, and dedication to helping pharmaceutical companies navigate complex regulatory requirements with confidence.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
